Defining a Medical Device in Russia: Intended Purpose and Mechanism Boundary

1. Key takeaways

The Russian definition of a medical device rests on a twin requirement of intended purpose plus mechanism of action: the product must be used for a medical purpose, and its principal intended action must not be achieved by pharmacological, immunological, genetic, or metabolic means. This two-part test determines whether a product enters the registration system at all, and it is applied before any question of risk class, testing scope, or dossier content arises. Products that fail the test, such as ordinary medicines, fall under pharmaceutical regulation instead, while products that pass it must be registered before circulation.

The assessment proceeds in three steps. First, examine the intended-purpose claims stated on the label and in the instructions for use, because these claims drive the entire classification. Second, determine whether the principal action relies on chemical reactions or metabolic processes within the body, which would point toward the medicinal product regime. Third, verify the type code in the nomenclature classification catalogue approved by Order No. 4n of the Ministry of Health. If all three steps point to a medical device, the product must be registered. Getting this sequence right at the start of a project prevents the costly discovery, mid-program, that the wrong regulatory regime has been assumed throughout.

The three-step test also disciplines internal decision-making. Marketing teams draft claims, distributors translate them, and software teams release updates, and each of these activities can quietly change the regulatory character of the product. By fixing the sequence of analysis, intended purpose first, mechanism of action second, catalogue verification third, and recording the outcome at each step, a manufacturer builds a defensible trail that shows why the product was treated as a device. That trail is exactly what an expert institution asks for when a product sits near the boundary, and having it prepared in advance turns a potentially disruptive query into a routine reply.

2. Legal basis

3. Expert insights

Insight 1: A subtle difference in wording can change the pathway. Russian law emphasizes that the principal action must not be achieved by pharmacological means, while the union agreement allows wording under which a medicinal substance may play a supporting role. For combination products such as drug-eluting stents or medicated dressings, this difference changes the judgment of the competent authority and the registration pathway itself. GRZAN recommends fixing the conclusion in writing at the classification stage, before any testing is commissioned, because reclassification after testing has begun can invalidate the entire evidence package and force the project to restart under a different framework with different expert institutions.

Insight 2: Standalone software is expressly in scope. The union classification rules treat autonomously operating software as an active medical device. In Russian practice, software with diagnostic, analytical, or clinical decision support functions likewise requires registration. The deciding factor is the clinical purpose that the software claims for itself, not how it is delivered: a product distributed on disc, by download, or from the cloud is judged by the same test. Manufacturers of digital health tools should therefore draft their intended-purpose statements with the same rigor they would apply to a physical instrument, since the claims in the software interface and marketing materials are treated as part of the regulatory record.

Insight 3: Purpose drift is the most common compliance incident. The same hardware registered in China as rehabilitation equipment can move into a higher risk class and a wider testing scope if the Russian-language instructions add a therapeutic claim. Every sentence in the registration documents concerning intended purpose should therefore pass regulatory review before release. The drift usually happens gradually: a distributor translates marketing material loosely, a tender response adds a use case, or a software update introduces a new analytical function, and the registered scope no longer matches what is actually offered to users.

4. Practical recommendations

1. Fix the Russian-language intended-purpose statement at the quotation stage, before contracts are signed, so that later pressure to add selling points does not force a rewrite of the instructions for use and a corresponding regulatory amendment.
2. For combination products, complete a one-time qualification as device, medicinal product, or biological product at project initiation, and retain a written record of the reasoning, including the mechanism-of-action analysis that supports it.
3. For software products, first document whether independent diagnostic or decision support functions are present, and only then determine the registration unit structure and the applicable evidence requirements.
4. Review all model and accessory claims against a single intended-purpose framework so that no variant of the product asserts a use outside the registered scope.

5. Verification checklist

• □ The Russian-language intended-purpose and performance claims have passed regulatory review
• □ The product can be matched to a type code in the catalogue of Order No. 4n
• □ Combination products have completed a device or medicinal product qualification with a written record
• □ Software products have been confirmed as active medical devices where applicable (including AI cases)
• □ The claims of all models and accessories fall within the same intended-purpose framework

GRZAN helps manufacturers apply the Russian definition of a medical device correctly from the first day of a project. Our team performs classification assessments against Federal Law 323-FZ and Order No. 4n, resolves device and medicinal product boundary questions for combination products, and reviews software intended-purpose claims for registration readiness. With experience across both RZN and EAEU pathways, GRZAN keeps classification decisions documented, defensible, and stable through the full registration lifecycle. For classification and registration support in Russia, contact GRZAN at info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.